SCHEMBL31366249

SCHEMBL31366249

CNC(=O)c1cnc(Cl)c(C)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.50
DPP4 P27487 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
RAB9A P51151 4/20 0.39
GAA P10253 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
BAZ2B Q9UIF8 1/20 0.39
KDM4E B2RXH2 1/20 0.38
GRM5 P41594 1/20 0.37
NPC1 O15118 3/20 0.36
CXCR3 P49682 2/20 0.36
PDK2 Q15119 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
PIP5K1C O60331 1/20 0.35
PIK3CA P42336 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29488827 0.81 ALDH1A1 (0.46) SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL4221972 0.81 ALDH1A1 (0.46) SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL12606629 0.79 SMN1; SMN2 (0.38) RAB9ASMN1; SMN2KDM4ENPC1POLB
SCHEMBL30420441 0.79 MAPK1 (0.43) RAB9ASMN1; SMN2KDM4ENPC1MAPT
SCHEMBL3710244 0.79 MAPK1 (0.43) RAB9ASMN1; SMN2KDM4ENPC1MAPT
SCHEMBL12606639 0.75 KMT2A (0.33) CNR1RAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL26106194 0.73
SCHEMBL16598296 0.73 GRIN2A (0.53) CNR1POLB
SCHEMBL17008794 0.72 GPR6 (0.42) CNR1RAB9AGAASMN1; SMN2GRM5
SCHEMBL422747 0.72 SIRT6 (0.57) CNR1RAB9AGAASMN1; SMN2BAZ2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425478-A1 CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS GENENTECH INC (US) 2024-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425478-A1 CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS CDK2, CCNI, CDK20 CNR1 2350/4885DPP4 3556/4885DPP8 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.